A Japanese study links external eating patterns to weight loss and glycemic improvements with glucagon-like peptide-1 receptor agonists.

A new large-scale study came to the conclusion that weight-loss surgery gives people with type 2 diabetes and obesity a ...

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving ...

An experimental GLP-1 pill called orforglipron promoted substantial weight loss without the need for weekly injections, ...

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with ...

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, ...

Please provide your email address to receive an email when new articles are posted on . Results showed 14 days may be the optimal cutoff for glucagon-like peptide-1 receptor agonists prior to hip or ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Glucagon-like peptide-1 agonists were not associated ...

MASLD is one of the pressing public health issues; yet, unfortunately, there is a scarcity of available pharmacological management options. GLP-1RAs have transformed the treatment landscape for ...

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted predominantly by intestinal enteroendocrine L cells in response to nutrient ingestion. By enhancing insulin secretion, delaying gastric ...

The intricate interplay between pancreatic beta cells and glucagon-like peptide-1 (GLP-1) has drawn considerable attention in efforts to improve the diagnosis and treatment of diabetes and insulinomas ...

This cohort study found that glucagon-like peptide-1 receptor agonist (GLP-1RA) prescriptions were associated with a lower risk of uveitis compared with controls. These findings suggest potential anti ...